Past Meetings

Past KinMet Meeting Programs

Washington 2001

  • Berman/Zech Award Lecture – ProcessDB: Development of a Database Tool Supporting Large Scale Modeling in Individual Laboratories. Robert D. Phair, BioInformatics Services, Rockville, MD
  • Overview of Apolipoprotein B Kinetics. Julian Marsh, New England Medical Center
  • Multi-compartmental Models of HDL Metabolism. Hugh Barrett, University of Western Australia
  • The Physiome Sciences vision: Integrated database and modeling tools for accelerating preclinical investigation. Thomas Colatsky, Physiome Sciences Inc, Princeton
  • Assembly and secretion of apoB from cultured hepatocytes: Insights derived from multicompartmental modeling. Nica Borradaile, Robarts Research Institute, London, Ontario
  • LpA-I kinetics in non-human primates and transgenic mice. John Parks, Wake Forest University, Winston-Salem
  • From Chaos to Specific Leads: Using the Integrated CellTek(TM) Simulation and Database Systems for Biological Pathway Prediction. John Armstrong, New World Science and Technology Inc, Silver Spring, MD
  • ApoB secretion in homozygous familial hypercholesterolemia. John Millar, University of Pennsylvania
  • Preliminary analysis of small Lp A-I turnover in human subjects. Perry Colvin, VA Hospital, Baltimore, MD
  • HDL Subspecies: Effects of Defective Reverse Cholesterol Transport, Inhibition of Cholesterol Synthesis, and Dietary Saturated Fat and Cholesterol Restriction in Humans. Bela Asztalos, Tufts University
  • KBTool: A simple, coherent, extensible strategy for managing biological information. Stephen Shaw, National Cancer Institute, NIH
  • ApoB Metabolism in Homozygous Tangier Disease: Effects of Defective Reverse Cholesterol Transport. Ernst Schaefer, Tufts University
  • Interrelationships between Human ApoB and ApoA-I Metabolism. Francine Welty, Harvard University
  • Future Directions for KinMet. Robert Phair, Bioinformatics Services, Rockville, MD

Salt Lake 2002

  • Levy Award Lecture – Apolipoprotein B Metabolism:  From Mice to Men” Henry Ginsberg, Columbia University College of Physicians and Surgeons
  • Berman/Zech Award Lecture – A history of modeling: Where are we today and where are we going? David Foster, University of Washington
  • An introduction to population kinetic analysis. Paolo Vicini, University of Washington
  • ApoCIII and apoE kinetics in VLDL of normolipidemic and hyperlipidemic humans. Jeffrey Cohn, Heart Research Institute, Sydney
  • The kinetics of the HDL apolipoproteins A-I, A-IV, and E within triglyceride-rich lipoproteins. Ernie Schaefer, Tufts University
  • Advances in Modeling Atherosclerotic Plaque Microvasculature in vivo. Andrew Hooker, University of Washington
  • Inhibition of both the apical sodium-bile acid  cotransporter and HMG-CoA reductase: Impact on the plasma kinetics of apolipoprotein B. Dawn Telford, University of Western Ontario
  • Differential effects of atorvastatin and fenofibrate of HDL apoAI metabolism. Hugh Barrett, University of Western Australia
  • HDL Metabolism in HDL Deficiency. Benoit Lamarche, Laval University

Washington DC 2003

  • Levy Award Lecture 1 – Application of Stable Isotope Methodology to Lipoprotein Metabolism. Julian Marsh, Tufts University
  • Levy Award Lecture 2 – ApoB Metabolism in Combined Hyperlipidemia: Application of Stable Isotope Methodology. Dennis Cryer, Bristol-Myers Squibb
  • Berman/Zech Award Lecture – Lipoprotein Cholesterol Ester Metabolism in Humans. Charles Schwartz, Virginia Commonwealth University
  • Intracellular trafficking of the ABCB11 Bile Acid Transporter. Irwin Arias, Tufts University
  • Commentary on cholesterol ester metabolism in rabbits. Hugh Barrett, University of Western Australia
  • Lipid Homeostasis: Gene Regulation through Protein Trafficking. Peter Espenshade, Johns Hopkins School of Medicine
  • ApoB Metabolism of Different VLDL Subspecies. Frank Sacks, Harvard University
  • HDL, CETP and HDL Subspecies Metabolism. Ernst Schaefer, Tufts University
  • Movement and homeostasis of cell cholesterol. Yvonne Lange, Rush-Presbyterian-St Luke’s Medical Center
  • Visualizing phosphoinositide dynamics in live cells. Tamas Balla, NICHD, NIH
  • Effects of Fenofibrate on Lipoprotein Metabolism. Hugh Barrett, University of Western Australia
  • Intracellular Trafficking of the ABCA1 Transporter. Ed Neufeld, NHLBI, NIH
  • Effects of statins on apoB metabolism. Muriel Caslake, Royal Infirmary, Glasgow
  • Apolipoprotein B48 kinetics using a stable isotope in heterozygotes for familial hypercholesterolemia carrying the same null LDL receptor mutation 1:45 Patrick Couture – Laval University –
  • Use of the multiple stable isotope approach to quantitate fatty acid sources in postprandial apoB-lipoproteins. Elizabeth Parks, University of Minnesota
  • Comments on writing rate laws for nonlinear models of cellular systems: Is it time to abandon the classical concept of concentration? Bob Phair, Integrative BioInformatics Inc

San Fransisco 2004

  • Levy Award Lecture – Advances in HDL Metabolism. Bryan Brewer, National Institutes of Health
  • A theoretical consideration in an integrated pool model for VLDL apoB and TG kinetics and delipidation. Sekhar Ramakrishnan, Columbia University
  • ApoB Kinetics in hepatic lipase deficient patients treated with fibrates. Benoît Lamarche, Laval University
  • Role of CETP in HDL metabolism and Atherosclerosis. Ernie Schaefer, Tufts University
  • HDL metabolism: a model of LpAI:AII kinetics. Hugh Barrett, University of Western Australia
  • Lipoprotein lipase bound to apoB lipoproteins in humans: role in clearance of postprandial lipoproteins. Chunyu Zheng, Harvard School of Public Health
  • Kinetics of apoB100 metabolism in miniature pigs following treatment with an inhibitior of 2,3- oxidosqualene cyclase: A novel cholesterol lowering agent. Murray Huff, University of Western Ontario

Washington 2005

  • Berman/Zech Award Lecture –  Modeling of Human Apolipoprotein A-I and B Metabolism. Hugh Barrett, University of Western Australia
  • Levy Award Lecture – Perspectives on VLDL and LDL ApoB-100 Metabolism-Insights that benefited Academia and Industry. David Bilheimer, Merck and Co. New Jersey
  • Effects of CETP Inhibition on Apolipoprotein A-I Metabolism in Humans. Margaret Brousseau, Tufts University
  • Using Mass Measurements in Fitting Apolipoprotein Tracer Data. Sekhar Ramakrishnan, Columbia University
  • Effects of phytosterols on lipoprotein metabolism in subjects with the metabolic syndrome. Esther Ooi, University of Western Australia
  • Commentary on Reverse Cholesterol Transport in Human Subjects from the perspective of Clinical Research and Kinetic Modeling. Charles Schwartz, Richmond, VA
  • Naringenin mimics the kinetics of insulin-induced inhibition of apoB100- containing lipoprotein assembly in HepG2 cells through a mechanism independent of the insulin receptor. Emma Allister, University of Western Ontario
  • Recycling of Apo(a), ApoA-I, and ApoA-IV on ApoB Containing Lipoproteins. Ernst Schaefer, Tufts University
  • Delipidation models for apoB48 and B100 metabolism in the postprandial period. Chun-yu Zheng
  • Transfer of dietary lipids into hepatocellular lipids and VLDL: An audience forum on FFA recycling. Elizabeth Parks, University of Minnesota
  • A novel inhibitor of oxidosqualene:lanosterol cyclase enhances LDL apoB100 catabolism through decreased hepatic cholesterol synthesis and enhanced expression of intestinal ABCG5 and ABCG8. Murray Huff, University of Western Ontario
  • Hepatic triglyceride synthesis and secretion in mice. John Millar, University of Pennsylvania
  • A New Model of Golgi Protein Trafficking that hightlights the Role of Membrane Lipids. Robert Phair, Integrative Bioinformatics Inc.

Denver 2006

  • Levy Award Lecture – HDL Metabolism. Katsunori Ikewaki, University of Jikei, Japan
  • Berman/Zech Award Lecture – Modeling of Triglyceride Metabolism with Stable Isotope Tracers, Bruce Patterson, Washington University
  • ApoB kinetics of lipoproteins containing apoE, apoCIII or both, Chunyu Zheng, Harvard University
  • Models of apoCIII metabolism: Interpretation of tracer data and effect of atorvastatin on apoCIII metabolism in overweight, dyslipidemic men. Hugh Barrett, University of Western Australia
  • Unexplained rapid clearance of modifed LDL tracers in cholesterol in primates: does it represent a novel pathway? Perry Colvin, Wake Forest University
  • Atheroprotection with Infusion of ApoA-I Mimetic Peptide. Marcelo Amar, NIH
  • One Reader’s Difficulties in Understanding Modeling Results. Sekhar Ramakrishnan, Columbia University
  • Using the kinetics of apoB100 metabolism to reveal the mechanism of action of ezetimibe plus simvastatin in miniature pigs. Murray Huff, University of Western Ontario
  • Effects of Moderate and High Dose Atorvastatin on HDL Metabolism, Margaret Diffenderfer, Tufts University
  • The Wonders of ApoB-48 ELISA. Elizabeth Teng Leary, Pacific Biometrics Inc.
  • Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia, Patrick Couture, Laval University
  • Kinetic studies using stable isotopes. Yasuhisa Kurogi, Cambridge Isotopes
  • Preliminary study of small dense LDL particle kinetics in humans. Benoît Lamarche, Laval University
  • Effects of CETP inhibition on apoB-100 kinetics. John Millar, University of Pennsylvania
  • Relationships between the Metabolism of TG rich Lipoproteins and HDL Particles. Ernst Schaefer, Tufts University

Chicago 2007

  • Berman/Zech Award Lecture – ApoB kinetics in TRL and LDL. Chris Packard, University of Glasgow
  • Levy Award Lecture – Effects of dietary factors on lipoprotein metabolism and atherosclerosis. Larry Rudell, Wake Forest University
  • Effect of Postprandial Fat and Carbohydrate Intake on the Kinetics of ApoB with apoE and with apoC-III. Frank Sacks, Harvard University
  • A mathematical model for CETP activity in vitro. Laura Potter, GlaxoSmithKline, Research Triangle Park
  • The metabolism of HDL subspecies in inborn errors of HDL metabolism. Bela Asztalos, Lipid Metabolism Laboratory, Tufts University
  • ApoB-48 metabolism in diabetes mellitus. Jean Charles Hogue, Laval University, Quebec
  • The importance of using isotopic enrichment standards to calibrate GC/MS measurements. Bruce Patterson, Washington University
  • Effects of CETP inhibition on human apolipoprotein metabolism. John Millar, University of Pennsylvania
  • The effects of Atorvastatin on apoB-48 metabolism. Margaret Diffenderfer, Lipid Metabolism Laboratory, Tufts University
  • In vivo metabolism of small dense LDL. Katsu Ikewaki, University of Jikei, Japan
  • HDL subfraction metabolism in monkeys. Chunyu Zheng , Harvard School of Public Health
  • Use of tracer-tracee Ratio (TTR) for enrichment Is largely a lipoprotein kinetic aberration. Sekhar Ramakrishnan, Columbia University
  • Dose-dependent improvement in HDL metabolism with Rosuvastatin in the metabolic Syndrome. Hugh Barrett, University of Western Australia

Atlanta 2008

  • Levy Award Lecture – Lipoprotein kinetics reveals the mechanism of action of lipid modifying drugs: Insights from cultured cells and animal models, Murray Huff, University of Western Ontario
  • New approaches to modelling postprandial data – Population kinetics and the possibilities? Hugh Barrett, University of Western Australia
  • ApoB Conversion Rate Constants Only As Good As the Pool Masses, Sekhar Ramakrishnan, Columbia University
  • The effect of TRL ApoE content, size and concentration on LDL uptake – A systems biology approach, Brendan O’Malley, Unilever, Bedford, UK
  • Non-CETP Mediated Transfer of HDL cholesteryl ester to LDL in mice, Marcelo Amar, National Institutes of Health
  • Dose-dependent effect of rosuvastatin on very-low density lipoprotein apolipoprotein C-III kinetics in men with the metabolic syndrome, Esther Ooi, University of Western Australia
  • Abnormal lipoproteins kinetics in ESRD HD patients, Katsu Ikewaki, Jikei University School of Medicine
  • Diurnal rhythm, and other factors, that influence lipogenesis, Elizabeth Parks, University of Texas Southwestern Medical School
  • Genetic Defects and Remodeling of HDL Particles, Ernst Schaefer, Lipid Metabolism Laboratory, Tufts University
  • Inhibition of cholesterol absorption by ezetimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs, Dawn Telford, University of Western Ontario
  • Effects of ezetimibe and simvastatin, coadministered and alone, on the in vivo kinetics of apoB-48 in patients with primary hypercholesterolemia Andre Tremblay, Laval University, Quebec City
  • Measurement of plasma free cholesterol flux: implications on cholesterol homeostasis, Marc Hellerstein, University of California, Berkeley
  • HDL turnover based on the behavior of apoA-I only particles, Larry Rudel, Wake Forest University
  • Modeling of oxylipin transport by lipoproteins,Greg Shearer, Sanford Research/University of South Dakota, Sioux Falls, SD
  • The effects of interventions on plasma free cholesterol flux and reverse cholesterol transport in animal models, Jason Voogt, KineMed, Emmeryville, CA
  • The Effects of Niacin on Human Apolipoprotein Metabolism, Margaret Diffenderfer, Lipid Metabolism Laboratory, Tufts University

Washington 2009

  • Berman/Zech Award Lecture – Tracer data are of enrichments. Why then do we model activities? Sekhar Ramakrishnan, Columbia University
  • Levy Award Lecture – Metabolic basis for hypertriglyceridemia and the dense LDL phenotype. Frank Sacks, Harvard University
  • HDL particle metabolism and proteomics. Bela Asztalos, Lipid Metabolism Laboratory, Tufts University
  • Modeling LDL interactions under flow in a bioreactor – a different playing field. Michael Fannon, University of Kentucky
  • Effects of CETP inhibition and LXR agonists on HDL-Cholesteryl ester kinetics in a hamster model. Francois Briand, Physiogenex S.A.S
  • Effect of a PPARdelta agonist on lipoprotein kinetics in the metabolic syndrome. Esther Ooi, School of Medicine and Pharmacology, University of Western Australia
  • Update on assessment of reverse cholesterol transport. Jason Voogt, KineMed, San Francisco
  • Effects of CETP inhibition on human apolipoprotein metabolism. Margaret Diffenderfer, Lipid Metabolism Laboratory, Tufts University
  • Isolating the influence of apoCIII on metabolism of VLDL and LDL in vivo. Carlos Mendivil, Harvard University
  • An overview of Lpa metabolism. Ernst Schaefer, Cardiovascular Research & Lipid Metabolism Laboratories, Tufts University
  • The kinetics apoB100-containing lipoprotein trafficking in HepG2 cells: The impact of insulin and the citrus flavonoid naringenin. Murray Huff, University of Western Ontario
  • Assessment of cholesterol synthesis and absorption in Familial Combined Hyperlipidemia. Thomas van Himbergen, Lipid Metabolism Laboratory, Tufts University
San Francisco 2010
  • Robert Levy Award Lecture – HDL Metabolism – What the Zebra Has Taught Us About the Horse. Ernie Schaefer, Tufts University
  • An approach to modeling tracer experiments in metabolic non-steady states. Robert D. Phair, Integrative Bioinformatics Inc.
  • From a Single Lipoprotein Profile to Metabolic Status Parameters Using Computational Modeling. Daan van Schalkwijk, TNO Quality of Life, Zeist & Leiden-Amsterdam CDR, Leiden University & Netherlands Bioinformatics Centre
  • If your apoB modeling software estimates any mass to be different from the average of your measurements, the software is likely to be wrong. Sekhar Ramakrishnan, Columbia University
  • A simplified mass-action model of cholesterol transport to predict disease phenotype in knock-out mice. Stewart Russell, New York University Medical Center
  • Configurator based dynamic modeling for reverse cholesterol transport. Sam Adhikari, Sysoft Center for Systems Biology and Engineering
  • Commutability of operations in SAAM modeling. Alex Glass, KineMed, Emeryville
  • Effect of a peroxisome proliferator actived receptor-d agonist on lipoprotein metabolism in patients with the metabolic syndrome. Esther Ooi, University of Western Australia
  • Plasma Lp(a) Metabolism: Disparate Kinetics of ApoB-100 and Apo(a). Peg Diffenderfer, Tufts University
  • ApoC-III and the metabolic basis for hypertriglyceridemia and the dense LDL phenotype. Frank Sacks, Harvard School of Public Health
  • Effect of ezetimibe on hepatic fat, inflammatory markers and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Wai Ng, University of Western Australia
  • CETP inhibitor Torcetrapib improves the severely impaired reverse cholesterol transport of obese insulin resistant CETP-apoB100 transgenic mice. Francois Briand, Physiogenex S.A.S, Labege, France
  • Modeling HDL subclasses: Experimental design and analysis of tracer data. Hugh Barrett, University of Western Australia
  • Serum Opacity Factor: A novel agent with a provocative mechanism for enhancing multiple RCT steps. Corina Rosales and Henry J Pownall, Baylor College of Medicine
  • An update on the measurement of RCT in vivo. Scott Turner, KineMed, Emeryville

Chicago 2011 

  • Robert Levy Award Lecture – Advancing Translational Science in Lipoprotein Metabolism: an Indispensable Role for Tracer Kinetics. Daniel Rader, University of Pennsylvania
  • Berman/Zech Award Lecture – Physiological validation of models of metabolism. Robert Wolfe, University of Arkansas for Medical Sciences
  • Modeling apoB48 mass and tracer kinetics in the postprandial setting. Hugh Barrett, University of Western Australia
  • Human CRP Metabolism is related to VLDL ApoB Metabolism. Margaret Diffenderfer, Tufts University
  • Theoretical Relationship Between HDL Size and the HDL-C/ ApoA-I Ratio. Norman Mazer, F. Hoffmann-LaRoche
  • Model-based diagnostic markers improve cardiovascular risk prediction in the Framingham cohort. Daan van Schalkwijk, TNO Quality of Life, Leiden University & Netherlands Bioinformatics Centre
  • Effects of fenofibrate and atorvastation on apolipoprotein E kinetics in the metabolic syndrome. Wai Ng, BakerIDI, Melbourne
  • An alternative method to measure in vivo macrophage-to-feces reverse cholesterol transport in hamsters. Francios Briand, Physiogenex, France
  • Modeling of non-steady state fatty acid dynamics yields evidence for insulin-sensitive fatty acid uptake. Robert D Phair, Integrative Bioinformatics Inc
  • Characterization and Kinetics of ApoA-II containing VLDL. Nirav Desai, Harvard School of Public Health
  • Modeling of HDL Particle Metabolism. Esther Ooi, Tufts University
  • Dynamic proteomics: using LC/MS/MS to measure the synthesis rates of proteins. Scott Turner, Kinemed, Emeryville, CA
  • ACAT2, ABCG5/G8 and their roles in cholesterol metabolism: is dogma correct? Tam Nguyen, Wake Forest University Medical Center
  • Mass Action Model of Cholesterol Exchange in Extravascular Tissue. Stewart Russell, New York University Medical Center
  • STARD4 abundance regulates intracellular sterol transport and sensing. Frederick Maxfield, Cornell Medical Center
  • A Triple-Tracer Approach Can Facilitate High-Throughput Studies of Apolipoprotein B Kinetics at Minimal Cost to Subjects and to Investigators. Sekhar Ramakrishnan Columbia University
  • HDL subfraction kinetics. Carlos Mendivil, Harvard School of Public Health

Chicago 2012

  • Robert Levy Award Lecture 1 – The Genetics of Atherosclerosis. Jan Breslow, Rockefeller University, NY
  • Robert Levy Award Lecture 2 – Human HDL Metabolism. Eliot Brinton, Foundation for Biomedical Research, Utah
  • Berman/Zech Award Lecture – From triglycerides to chylomicrons and back to triglycerides. Anh Le, Emory University, GA
  • Variability in the absorption of dietary fat and its contribution to the plasma FFA pool. Elizabeth Parks, UT Southwestern Medical Center, TX
  • Impact of adding MUFA to a portfolio diet of cholesterol-lowering foods on the in vivo kinetics of apolipoproteins AI, B100 and B48 in subjects with hypercholesterolemia. Marie-Ève Labonté, Laval University, Quebec
  • The real world is noisy, and how you weight your data can affect the results of your modeling. Sekhar Ramakrishnan, Columbia University, NY
  • Effect of atorvastatin on very low-density lipoprotein triglyceride kinetics in obese men. Esther Ooi, University of Western Australia
  • Further Development of a Stochastic In Silico Model of Lipoprotein Metabolism and Kinetics in Humans (LMK Model): Focus on Dynamics of CETP-Mediated Lipid Transfer. Norman Mazer, Department of Translational Research Sciences, F. Hoffman – La Roche Ltd., Basel
  • Advances in Dynamic Proteomics – Kinetic analysis of the Apo lipoproteome in man. Scott Turner, KineMed Inc, Emeryville, CA
  • Metabolism of large and small LDL. Margaret Diffenderfer, Tufts University, MA
  • Effect of Niacin on HDL apoAI Kinetics in Statin-Treated Type 2 Diabetes. Hugh Barrett, University of Western Australia
  • Effects of atorvastatin on CRP metabolism. Ernst Schaefer, Tufts University, MA
  • Mechanism by which Anacetrapib Lowers Plasma Lipoprotein (a) Concentration. Tiffany Thomas, Columbia University, NY
  • HDL kinetics in mouse models using an MRI sensitive tracer. Stewart Russell, New York University School of Medicine, NY
  • Non-steady state tracer kinetic modeling in the context of fatty acid metabolism. Robert Phair, Integrative Bioinformatics Inc, Sunnyvale, CA
  • The effects of rosuvastatin on sphingolipids and phospholipids in the metabolic syndrome – a case for pursuing tracer lipidomics. Wai Ng, BakerIDI, Melbourne, Australia
  • Effect of weight loss, independent of nutrient intake, on apoAI kinetics in men with the metabolic syndrome. Caroline Richard, Laval University, Quebec

Lake Buena Vista 2013

  • Robert I Levy Memorial Lecture: The Regulation of LDL Metabolism. Gloria Vega, UT Southwestern Medical Center, Dallas
  • Kinetic virtual biopsy. Scott Turner, KineMed Inc, Emeryville, CA
  • Does CETP inhibition promote reverse cholesterol transport? Lessons from animal models. Francois Briand, Physiogenex S.A.S
Prologue Biotech, Labège,
 France
  • Anacetrapib affects Triglyceride kinetics in Rhesus Macaques: Mechanistic insights on LDL-C lowering. David G. McLaren. Merck Research Laboratories    
  • Elucidating the interrelationships between reverse cholesterol transport rate, HDL-C and pre-beta fraction using a new in silico model of lipoprotein metabolism and Kinetics. Norman Mazer, Hoffmann-La Roche, Ltd., Basel, Switzerland
  • A practical method for measuring isotope enrichment in low abundant proteins: CETP & PCSK9. Michael Lassman, Merck Clinical Development Laboratory
  • PCSK9 metabolism in humans. John Millar, University of Pennsylvania, PA
  • Propagation of analytical error in tracer studies of lipid and protein flux. Stephen Previs, Merck
  • An introduction to kinetic modeling in dietary non-steady states. Robert Phair, Integrative Bioinformatics Inc, Mountain View, CA
  • Analytic results for some simple nonsteady-state situations. Sekhar Ramakrishnan, Columbia University, NY
  • ApoB-48 kinetics in the postprandial state. Hugh Barrett, University of Western Australia, Perth
  • The effects of medium-chain TG on TRL apoB-48 and apoB-100 kinetics in insulin-resistant men. Patrick Couture, University of Laval, Quebec
  • Effect of the Mediterranean diet on apolipoprotein B kinetics in men with the metabolic syndrome. Caroline Richard, University of Laval, Quebec
  • Lp(a) metabolism in statin-treated patients with type 2 diabetes. Esther Ooi, University of Western Australia, Perth
  • The effects of rosuvastatin on the metabolism of large and small LDL apoB. Margaret Diffenderfer, Tufts University
  • Composition of large and small LDL; Implications for its metabolism. Sampath Parthasarathy, University of Central Florida
  • The effects of ApoA-I truncation on HDL metabolism. Pimjai Anthanont, Tufts University
  • Metabolism of HDL subfractions in humans who have low or high HDL-C levels. Frank Sacks, Harvard University
  • Proteomics of individual apoA-I containing particles. Bela Asztalos, Tufts University
  • The effects of CETP inhibition on HDL and CETP kinetics. Gissette Reyes-Soffer, Columbia University, NY

Toronto 2014

  • Levy Award Lecture: Metabolic abnormalities in FH: more than meets the eye. Gerald Watts, University of Western Australia
  • Berman/Zech Award Lecture: HDL and Cholesterol Transport. Michael Phillips, Children’s Hospital of Philadelphia
  • Deuterated water: A single tracer for simultaneous measurement of lipid and protein turnovers. Tiffany Thomas, Columbia University
  • Kinetics of the apolipoproteome. Scott Turner, KineMed Inc
  • Fractional standard deviations (FSD’s) from modeling software: how to and where not to use them. Sekhar Ramakrishnan, Columbia University
  • Lp(a) metabolism in statin-treated patients with type 2 diabetes.Esther Ooi, University of Western Australia 
  • Differential regulation of intestinal and hepatic lipoprotein production. Gary Lewis, University of Toronto
  • Glucagon Like Peptide-2 (GLP-2) is a Novel Regulator of Chylomicron Release from the Intestine. Satya Dash, University of Toronto
  • Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes. Patrick Couture, Laval University
  • Regulation of Intestinal ApoB Production. Khosrow Adeli, Hospital for Sick Children & University of Toronto
  • Niacin improves basal and postprandial apoB-48 metabolism in statin-treated diabetics. Hugh Barrett, University of Western Australia
  • Interrelationships between TC, LDL-C, non HDL-C, apoB, LDL-P, and small dense LDL-C. Ernst Schaefer, Tufts University
  • Interrelationship between in vivo metabolism of apolipoprotein B100 containing lipoproteins and the LDL particle size phenotype in men. Benoit Lamarche, Laval University
  • Integrative Biology of Cellular Cholesterol Trafficking and Efflux. Bob Phair, Integrative Bioinformatics Inc
  • HDL Turnover and Reverse Cholesterol Transport. Takhar Kasumov, Cleveland Clinic
  • Reverse cholesterol transport in humans. Marina Cuchel, University of Pennsylvania
  • Metabolism of apoA-I in four sizes of HDL in participants with low or high HDL. Frank Sacks, Harvard University

San Francisco 2015

  • Levy Award Lecture: Molecular Speciation and Function of High Density Lipoproteins: The New Era. John Kane, University of California, San Francisco.
  • Berman/Zech Award Lecture: Can We Make Molecular Kinetics Routine and Useful in Medical Practice and Drug Development? Marc Hellerstein, University of California, Berkeley and KineMed Inc.
  • Population Based Interrelations Between Lipoprotein Subclasses. Ernst Schaefer, Tufts University, Boston.
  • Ezetimibe prevents atherogenesis through increased catabolism and fecal excretion of LDL-cholesterol and reduced atherosclerotic plaque inflammation in apolipoprotein E knock-out mice fed a Paigen diet.François Briand, Physiogenex SAS, Labege, France.
  • Omega-3 acid ethyl esters partially correct the dysfunctional trafficking of non-esterified fatty acids in insulin resistant subjects.Greg Shearer, Penn State University, PA.
  • Steady state contribution of de novolipogenesis to circulating lipids in NASH and NAFLD. Scott Turner, KineMed Inc, Emmeryville, CA.
  • Association between insulin-resistance, inflammation and TRL apoB-48 kinetics.Jean-Philippe Drouin-Chartier, Laval University, Québec City.
  • Effects of inhibiting apoB synthesis on VLDL secretion: not what you might have expected. Henry Ginsberg, Columbia University, NY. 
  • A novel QTOF method for the determination of isotopic enrichment in apolipoproteins.Margaret Diffenderfer, Tufts University, Boston.
  • Comparison of apolipoprotein B kinetics modeled using prior studies’ averaged amino acid parameters rather than plasma amino acid enrichments from each study. Marianna Pavlyha, Columbia University, NY.
  • Modeling the VLDL delipidation cascade: apolipoprotein B and triglyceride pools have identical rate constants despite different fates and mass distributions. Sekhar Ramakrishnan, Columbia University, NY.
  • Effect of Niacin on apoB-containing lipoproteins and Lp(a) kinetics in statin-treated patients with type 2 diabetes. Esther Ooi, University of Western Australia.
  • A perspective on the state of biomedical kinetic modeling in 2015. Robert Phair, Integrative Bioinformatics Inc, Mountain View, CA. 
  • The role of STARD4 in intracellular sterol transport.Fred Maxfield, Weill Cornell Medical College, NY.
  • Unique distribution and metabolism in vivo of HDL proteins apoA-I, apoA-II, apoA-IV, apoC-III, apoD, apoE, and apoM across HDL size in humans. Allison Andraski, Harvard University, MA.
  • ApoE accelerates the kinetics in vivo of apoA-I in 4 sizes of HDL in humans.Allyson Morton, Harvard University, MA.

Nashville 2016

  • Levy Award Lecture: Fatty acid kinetics and late-night lipid metabolism. Elizabeth Parks, Nutrition and Exercise Physiology, University of Missouri, MO
  • Error in determining FSR from the enrichment upslope of a slow protein can be avoided by fitting the downslope of its complement. Steve Holleran, Columbia University, NY
  • CETP in Estrogen-Regulated Glucose and Triglyceride Metabolism: Roles of CETP beyond HDL. John Stafford, Vanderbilt University, TN
  • FCRs, binding constants, and the mechanism of PCSK9. Bob Phair, Integrative Bioinformatics Inc, CA 
  • The role of liver AMPK on glucose producing and related nutrient fluxes during exercise. Curtis Hughey, Vanderbilt University, TN
  • Use of Plasma Sterol Measurements for the Assessment of Cholesterol Production and Absorption and the Diagnosis of Phytosterolemia and Cerebrotendinous Xanthomatosis, Ernst Schaefer, Tufts University, MA
  • ApoB100 kinetics in LDLR-deficient Yucatan minipigs, a new model for familial hypercholesterolemia. Dawn Telford, University of Western Ontaria, London, Ont
  • Novel lipid lowering treatments: effects on Lp(a) levels and metabolism. Gissette Soffer, Columbia University, NY 
  • Effects of bariatric surgery on postprandial triglyceride rich lipoprotein metabolism. Marie Maraninchi, Marseille Université 
  • Berman/Zech Award Lecture: Measuring kinetics with stable isotopes: Apolipoproteins, PCSK9 and beyond. John Millar, Perelman School of Medicine, University of Pennsylvania, PA
  • Cellular PIP2 is effluxed by ABCA1 to apoA1 and PIP2 is carried on HDL that can be delivered to target tissues via SR-B1. Kailash Gulshan, Cleveland Clinic, OH 
  • ApoE and ApoCIII Interact to Modulate the Metabolism of HDL ApoA-I In Humans. Allyson Morton, Harvard, MA
  • Distribution of the HDL proteome and the in vivo metabolism of apoA-I, apoA-II, apoA-IV, apoC-III, apoD, apoE, and apoM across 5 HDL size fractions in humans. Allison Andraski, Harvard, MA  
  • HDL Metabolism: The Alternative way. Bela Asztalos, Tufts University, MA

Minneapolis 2017

  • Berman/Zech Award Lecture: The Control of Energetic Status and Mitochondrial Substrate Utilization in Health and Disease. Daniel Beard, University of Michigan
  • Partial Integro-Differential Equation Models Structured by Lipid Accumulation Reveal the Dynamics and Fate of Monocyte-Derived Cells in Atherosclerosis. Hugh Ford, University of Sydney.
  • Partial Integro-Tracer Kinetics in Molecular Cell Biology. Bob Phair, Integrative Bioinformatics, Inc., CA
  • HDL Cholesterol Kinetics. John Millar, University of Pennsylvania
  • The Effects of Inflammation on Polyunsaturated Fatty Acid Incorporation in VLDL, and Its Associations with Oxylipin Composition. Rachel Walker, Penn State University
  • HDL Subparticle Kinetics – Research in Progress. Hugh Barrett, University of Western Australia.
  • The Role of Glycation in HDL Instability and Dysfunction in Patients with Type 2 Diabetes. Takhar Kasumov, Northeast Ohio Medical University.
  • The Effect of Diet on the Metabolism of ApoA-I on HDL Containing or Not Containing ApoE. Allyson Morton, Harvard University
  • Generation of photoactivatable apoA1 to study HDL transport in vivo reveals impaired HDL recirculation in a murine model of psoriasis. Li-Hao “Paul” Huang, Washington University.
  • HDL Particles & Lipoprotein Metabolism. Ernie Schaefer, Tufts University.
  • Levy Award Lecture: Advances in Triglyceride-Rich Lipoproteins and Lipoprotein(a).Joseph Witztum, University of California, San Diego.
  • Triglyceride and apoB Turnover in Subjects with apoC-III R19X Mutation. Gissette Reyes-Soffer, Columbia University.
  • “One thing we all agree on, that plasma volume is 45 mL/kg, seems unsupported by evidence.”. Sekhar Ramakrishnan, Columbia University.
  • Lp(a) Metabolism. Henry Ginsberg, Columbia University.

See the program here